New cardiovascular drugs 1986

New oral anticoagulant drugs in cardiovascular disease.

Oral anticoagulation has been limited to vitamin K antagonists (VKAs) for over 60 years. VKAs are effective and recommended for the prevention of venous and arterial thromboembolism in cardiovascular disease, but their pharmacodynamics are difficult to predict and the highly variable interindividual and intraindividual response to treatment accounts for the need of continuous monitoring. This p...

Poisonings by Cardiovascular Drugs in Yekaterinburg, Russia

Background: The pattern of poisoning in Russia may be different from other countries. The study objective was to describe the pattern of poisoning with cardiovascular drugs in a major industrial city in Russia, Yekaterinburg. Methods: This study was part of a larger prospective multi-center study including all acute poisonings in patients older than 15 years of age in the city of Yekaterinburg...

Biotechnology and the pharmaceutical industry. New cardiovascular drugs.

Why So Few New Cardiovascular Drugs Translate to the Clinics.

There are multiple reasons for the failure to successfully translate new drugs to the clinics. One reason, noted by others, is the lack of reproducibility of studies and the problems with accuracy and rigor. However, another reason for translational failure has not been emphasized by others, that is, the lack of state-of-the-art cardiovascular measurements, because of effects of anesthesia, lac...

Why So Few New Cardiovascular Drugs Translate to the Clinics

There are multiple reasons for the failure to successfully translate new drugs to the clinics. One reason, noted by others, is the lack of reproducibility of studies and the problems with accuracy and rigor. However, another reason for translational failure has not been emphasized by others, that is, the lack of state-of-the-art cardiovascular measurements, because of effects of anesthesia, lac...